John Olsen
Psychiatry · Foley, ALNPI 1962085233
Payments from drug & device makers
Across 167 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$624
- Teva Pharmaceuticals USA, Inc.$463
- Otsuka America Pharmaceutical, Inc.$454
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$449
- Alkermes, Inc.$411
- Vanda Pharmaceuticals Inc.$222
- plus $960 from 9 others
What the payments were for
- Food & beverage$3,39095%
- Education$1925%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 21 | $624 |
| Teva Pharmaceuticals USA, Inc. | 15 | $463 |
| Otsuka America Pharmaceutical, Inc. | 30 | $454 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $449 |
| Alkermes, Inc. | 19 | $411 |
| Vanda Pharmaceuticals Inc. | 9 | $222 |
| Indivior Inc. | 7 | $215 |
| AbbVie | 16 | $205 |
| Corium, LLC | 9 | $141 |
| Johnson & Johnson | 6 | $117 |
| E.r. Squibb & Sons, L.L.C. | 6 | $100 |
| Lundbeck LLC | 5 | $89 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
How this compares
$3,582 in reported general payments places this provider in the 80th percentile of 400 psychiatry providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 29 | $14,859 |
| BelsomraSuvorexant | 14 | $7,895 |
| Aripiprazole | 70 | $3,540 |
| Atomoxetine Hcl | 23 | $2,012 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 67 | $1,288 |
| Duloxetine Hcl | 63 | $1,189 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $990 |
| Quetiapine Fumarate | 69 | $927 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 21 | $819 |
| Buspirone Hcl | 27 | $578 |
| Trazodone Hcl | 94 | $533 |
| Fluoxetine Hcl | 45 | $510 |
| Mirtazapine | 22 | $493 |
| Temazepam | 20 | $430 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 17 | $404 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $18 | $14,85929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Foley
- Matthew MacalusoBirmingham$2.8M
- Richard SheltonBirmingham$2.4M
- Michael FalolaTrussville$2.2M
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Lori DavisTuscaloosa$515K
- Scariya KumaramangalamHuntsville$440K
- Mark HaygoodMobile$348K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.